Pharmacokinetics of single and repeat doses of icatibant.

about

Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients.

P2860

Q47796115-5ADB47CA-1329-4389-9337-3F4D358B9E86

P2860

Pharmacokinetics of single and repeat doses of icatibant.

Item

http://www.wikidata.org/entity/Q53111655

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Pharmacokinetics of single and repeat doses of icatibant.

@en

Pharmacokinetics of single and repeat doses of icatibant.

@nl

type

Item

label

Pharmacokinetics of single and repeat doses of icatibant.

@en

Pharmacokinetics of single and repeat doses of icatibant.

@nl

prefLabel

Pharmacokinetics of single and repeat doses of icatibant.

@en

Pharmacokinetics of single and repeat doses of icatibant.

@nl

P1476

Pharmacokinetics of single and repeat doses of icatibant.

@en

P2093

J Kevin Leach

http://www.w3.org/2001/XMLSchema#string

Kelly Spencer

http://www.w3.org/2001/XMLSchema#string

Maryann Mascelli

http://www.w3.org/2001/XMLSchema#string

Thomas G McCauley

http://www.w3.org/2001/XMLSchema#string

P2860

Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.

Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema.

Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor

Formation of bradykinin: a major contributor to the innate inflammatory response.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema.

Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.

The plasma bradykinin-forming pathways and its interrelationships with complement.

Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems.

Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.

P304

105-111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPDD.138

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27128215

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetics of single and repeat doses of icatibant.

about

P2860

P2860

Pharmacokinetics of single and repeat doses of icatibant.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698